Sign in
Taking people in United StatesPhase 4

CytoGam after antiviral treatment to prevent late CMV after liver or kidney transplant

Tests CytoGam in high-risk liver or kidney transplant recipients to prevent late CMV disease.

Key facts

Who runs it
Camille N. Kotton, MD
Where
Boston and Dallas, United StatesSee the 2 sites
Trial code
Registry title
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
Status
Recruiting
Phase
Phase 4
People taking part
80 people, planned
Started
27 Nov 2025
Expected to end
31 May 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
Record updated
22 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who got a kidney, liver, or combined liver-kidney transplant and are at high risk of late CMV infection. It tests CytoGam® after preventive antiviral treatment ends.

Age
18 to 75 years
Sex
All sexes
Disease stage
Kidney, liver, or simultaneous liver-kidney transplant recipients at high risk: the donor had CMV antibodies and the recipient did not (D+R-).
Earlier treatment
Coming to the end of standard preventive antiviral treatment (valganciclovir prophylaxis). People treated for organ rejection within three months before the end of valganciclovir prophylaxis cannot join.
Biomarker or test result
Before transplant: donor CMV IgG positive and recipient CMV IgG negative (CMV D+/R-).

Main reasons for not taking part

  • Any other CMV donor/recipient antibody combination than D+/R-
  • Other multi-organ transplants, lung, heart, small bowel or pancreas transplants, or a past bone marrow or stem cell transplant
  • eGFR <30 ml/min/1.73m2, poor transplant organ function, being on dialysis or plasmapheresis, or relisted for transplant
  • Severe reaction to CMV immunoglobulin or other human immunoglobulin, or selective immunoglobulin A deficiency
  • Pregnant or breastfeeding women, or women who can become pregnant and do not use highly effective birth control

This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: * High risk pretransplant CMV donor seropositive/recipient seronegative (D+R-) kidney, liver, or simultaneous liver-kidney (SLK) transplant recipients

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • High risk pretransplant CMV donor seropositive/recipient seronegative (D+R-) kidney, liver, or simultaneous liver-kidney (SLK) transplant recipients
  • Able to do routine blood testing (normal care for transplant recipients)
  • Written informed consent obtained from the subject before any trial-related procedures
  • Be ≥18 years and ≤75 years of age at time of consent

Who cannot take part

  • Any pre-transplant CMV serologic combinations besides CMV D+/R-
  • Multi organ transplants (other than simultaneous liver-kidney transplant (SLK) recipients) or prior history of bone marrow or stem cell transplant
  • Transplant recipients treated for rejection within three months before the end of valganciclovir prophylaxis
  • Participation in another interventional clinical trial at time of consent or within 30 days prior to study consent
  • Individuals with a history of selective immunoglobulin A deficiency will be excluded, as they may produce antibodies against immunoglobulin A, leading to potential anaphylactic reactions upon receiving blood products containing immunoglobulin A, such as CMV immunoglobulin (e.g. CytoGam® or similar)
  • Women of childbearing potential unless using a highly effective method of contraception during dosing and for 24 weeks after study treatment. Medically acceptable birth control (contraceptives) includes but are not limited to: surgical sterilization (such as hysterectomy or "tubes tied"), approved hormonal contraceptives (such as birth control pills, patch or ring; Depo-Provera, Depo-Lupron, lmplanon), barrier methods (such as condom or diaphragm), an intrauterine device (IUD), abstinence from sex
  • Lung, heart, small bowel, pancreas, or other non-kidney or non-liver transplant recipients
  • Those with a history of severe reaction to CMV immunoglobulin (e.g. CytoGam® or similar) or other human immunoglobulin preparations
  • Any history of acute myocardial infarction (within 12 months of screening), clinically significant arrythmia, or clinically significant ECG abnormality in the opinion of the investigator at time of screening
  • History of active or latent tuberculosis (except those who have completed a documented regimen for latent TB treatment) or severe pulmonary disease [e.g., severe pulmonary hypertension (WHO class IV)] that in the opinion of the investigator that may preclude their ability to safely tolerate study infusions
  • Any history of neurodegenerative disease, including dementia, or stroke with substantial residual disability (modified Rankin score ≥ 3)
  • Any significant history of any treatment nonadherence or any other medical condition that, in the investigator's opinion, would confound the results of the study or put the participant at undue risk
  • Transplant recipients with eGFR <30 ml/min/1.73m2 (as they theoretically could be at higher risk for renal impairment with CMV immunoglobulin), poor transplant organ function (i.e. LFTs > twice the upper limit of normal in liver recipients), or who are on dialysis, or plasmapheresis, or who are relisted for transplant, or who might otherwise at risk of complications at the discretion of the local site investigator
  • Pregnant or nursing (lactating) women confirmed by human chorionic gonadotropin (hCG) laboratory test
  • Subjects who have any of the following laboratory values: eGFR <30 ml/min/1.73m2 ; Hemoglobin <8.0 g/dL; Platelets <50,000 cells/uL; Absolute neutrophil count <1,000 cells/uL; Total bilirubin >2.5 x upper limit of normal; Alanine aminotransferase (ALT) >5 x upper limit of normal; Aspartate aminotransferase (AST)] >5 x upper limit of normal; CMV IgG negative in donor or positive in recipient

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Massachusetts General HospitalBoston, United StatesContact: MGH Abdominal Transplant UnitTaking people
  • University of Texas, SouthwesternDallas, United StatesContact: Jarrett Hubbard, BATaking people

About the trial

What the trial wants to find out

This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.

The 2 groups in the trial

  • Arm A: CytoGam®Treatment being tested

    Participants assigned to receive CytoGam® will receive an infusion once a month for three months at their study site. The infusion will be completed over an average of about 4 hours; these three visits will last about 5 hours. During these study staff will review concomitant medications and adverse events. Participants will be asked to have blood taken at infusion visits and 2 weeks after an infusion visit to check the level of CMV DNA in their blood.

    Treatment: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months

  • Arm B: Standard of CareNo study treatment, for comparison

    Participants assigned to Arm B, will be asked to complete a telephone call visit once a month. During these visits, a member of study staff will review concomitant medications and adverse events. Participants will be asked to have their blood taken every two weeks to check the level of CMV DNA.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Exploratory Use of CMV Immunoglobulin in High Risk (D+R-) Transplant Recipients at the End of Antiviral Prophylaxis to Decrease the Risk of Late CMV Infection
Plain-language title
CytoGam after antiviral treatment to prevent late CMV after liver or kidney transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06958796, who can take part
Record updated
22 December 2025